EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergistic Biomedical Potential and Molecular Docking Analyses of Coumarin–Triazole Hybrids as Tyrosinase Inhibitors: Design, Synthesis, In Vitro Profiling, and In Silico Studies

Rukhsana Kausar, Ameer Fawad Zahoor iD, Hina Tabassum, Shagufta Kamal, Mashooq Ahmad Bhat iD

Pharmaceuticals · 20.04.2024 · 17 (4) · 532

DOI: 10.3390/ph17040532 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 20.04.2024. Verfasst von Rukhsana Kausar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Government College University Faisalabad, Faisalabad 38000, Pakistan. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Saud University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The tyrosinase enzyme has a vital role in the browning of vegetables and fruits and the biosynthesis of melanin. In this work, we synthesized a diverse library of coumarin–triazole hybrids, and these compounds were characterized by using suitable analytical techniques. Our research work extends beyond the synthetic effort to explore the therapeutic potential of these compounds. We put the synthesized compounds through meticulous in vitro screening against the tyrosinase enzyme, and these coumarin derivatives evinced good IC50 values in the range of 0.339 ± 0.25 µM to 14.06 ± 0.92 µM. In the library of synthesized compounds, six compounds were found to be more potent than standard ascorbic acid (IC50 = 11.5 ± 1.00), and among them, 17e and 17f, being the most active, exhibited remarkable anti-tyrosinase potential, with IC50 values of 0.339 ± 0.25 μM and 3.148 ± 0.23 μM, respectively. Furthermore, an in silico modeling study was carried out to determine the key interactions of these compounds with the tyrosinase protein (PDB ID: 2Y9X) and thus to authenticate our experimental findings. The quantitative SAR studies exhibited a good correlation between the synthesized derivatives of coumarin and their anti-tyrosinase activity. The docking studies verified the experimental results, and ligand 17e showed good interaction with the core residues of tyrosinase. This study not only expands the field of coumarin–triazole hybrid synthesis but also provides valuable insights for the development of novel tyrosinase inhibitors.

Schlagwörter

Stichwörter der Autor:innen

coumarinsynthesistriazolestyrosinase inhibitors

Autor:innen und Institutionen

  • Department of Chemistry, Government College University Faisalabad, Faisalabad 38000, Pakistan.
  • Department of Pharmacology, London Metropolitan University, 166-220 Holloway Road, London N7 8DB, UK.
  • Department of Biochemistry, Government College University Faisalabad, Faisalabad 38000, Pakistan.
  • Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.

ORCID-Profile: Ameer Fawad Zahoor, Mashooq Ahmad Bhat

Förderung

  • King Saud University

Zitieren

APA

Kausar, R., Zahoor, A. F., Tabassum, H., Kamal, S., & Ahmad Bhat, M. (2024). Synergistic Biomedical Potential and Molecular Docking Analyses of Coumarin–Triazole Hybrids as Tyrosinase Inhibitors: Design, Synthesis, In Vitro Profiling, and In Silico Studies. Pharmaceuticals, 17(4), 532. https://doi.org/10.3390/ph17040532

Vancouver

Kausar R, Zahoor AF, Tabassum H, Kamal S, Ahmad Bhat M. Synergistic Biomedical Potential and Molecular Docking Analyses of Coumarin–Triazole Hybrids as Tyrosinase Inhibitors: Design, Synthesis, In Vitro Profiling, and In Silico Studies. Pharmaceuticals. 2024;17(4):532. doi:10.3390/ph17040532

BibTeX
@article{Kausar2024,
  author = {Kausar, Rukhsana and Zahoor, Ameer Fawad and Tabassum, Hina and Kamal, Shagufta and Ahmad Bhat, Mashooq},
  title = {Synergistic Biomedical Potential and Molecular Docking Analyses of Coumarin–Triazole Hybrids as Tyrosinase Inhibitors: Design, Synthesis, In Vitro Profiling, and In Silico Studies},
  journal = {Pharmaceuticals},
  year = {2024},
  volume = {17},
  number = {4},
  pages = {532},
  doi = {10.3390/ph17040532}
}
Kostenlos starten →